Our pipeline
Shaping the future of medicine
Our pipeline is grounded in robust scientific research and focused on developing well-tolerated therapies for rare cardiovascular and pulmonary diseases with high unmet medical need.
Cereno Scientific’s vision is to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the fullest.
Rare diseases with high unmet needs
A science-driven approach targeting underlying disease biology
Cereno Scientific is advancing a differentiated pipeline focused on rare cardiovascular and pulmonary diseases where current treatment options remain limited. Our pipeline includes two clinical-stage HDAC inhibitor programs, acting through epigenetic modulation, and one preclinical program targeting rare thrombotic disorders.
Together, these programs reflect a long-term scientific approach aimed at pioneering treatments through well-tolerated therapies that address key disease mechanisms.
Epigenetic modulation through HDAC inhibition
Cereno Scientific’s ambition is built around a novel disease-modifying approach targeting the underlying pathophysiology of a range of cardiopulmonary diseases.
CS1 in PAH
CS1 is a well-tolerated oral therapy with favorable safety profile and disease-modifying effects in development for the rare disease pulmonary arterial hypertension (PAH). A Phase IIa trial has successfully been completed and preparations for a Phase IIb is ongoing.
CS014 in PH-ILD
CS014 is targeting pulmonary hypertension associated with interstitial lung disease (PH-ILD) as a differentiated oral therapy. It’s a once-daily HDAC inhibitor with favorable safety and tolerability. Preparations for a Phase II trial is ongoing.
CS585 in rare thrombotic disorders
CS585 represents a novel approach to the treatment of thrombosis without increased bleeding risk, which is a key limitation of current therapies. Preclinical development is ongoing.
Changing the lives of patients
Patients
At Cereno Scientific, patients are at the center of everything we do. We are committed to developing well-tolerated oral treatments for people living with rare and serious cardiovascular and pulmonary diseases, where current options are often limited.
By building on strong science and a deep understanding of disease biology, we aim to improve quality of life and address areas of significant unmet medical need.
News
View allPress release
10 Apr 2026
Cereno Scientific to Participate at Nordic Health Summit Japan and ChinaBio Partnering Forum 2026
Press release
04 Apr 2026
Cereno Scientific Highlights Strategic Value of Meeting Primary Endpoint of Safety and Tolerability of 12-month CS1 Data in PAH
Press release
31 Mar 2026
Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program
For Investors
Go to InvestorsCRNO.B
The SharePresentations
View all
Invest in Cereno
Deeper insights
Stories
Insights and explainers to support understanding of the field, our activities and why innovation in medicine matters.
Story
How to interpret the strategic value of the 12-month EAP data for CS1 – clarity on what this means for investors
Cereno Scientific recently confirmed that CS1 met its primary endpoint of safety and tolerability in the 12-month Expanded Access Program (EAP) with CS1 in pulmonary arterial hypertension (PAH), confirming that CS1 was well tolerated with a favorable safety profile . While based on a limited number of patients, the EAP represents an important step forward by adding longer-term clinical data to the CS1 program. The initial analysis of the EAP has been focused on the primary endpoint of safety and tolerability. Further analyses will be conducted on data from the EAP and Fluidda imaging sub-study evaluating changes in the pulmonary vessels during Q2 2026.
Story
Vad initiala insikter från EAP innebär för den fortsatta utvecklingen av CS1 – en förklaring för investerare
Cereno Scientific har presenterat initiala insikter från ett Expanded Access Program (EAP), där patienter med pulmonell arteriell hypertension (PAH) behandlats med läkemedelskandidaten CS1 under 12 månader. Resultaten bekräftar en gynnsam säkerhets- och tolerabilitetsprofil vid långtidsbehandling och är i linje med tidigare resultat från Fas IIa-studien. I denna artikel förklarar vi vad resultaten innebär, varför de...
Story
Så ska godkännandet av CS014-studien förstås – en förklaring för investerare
Cereno Scientific meddelade idag att Läkemedelsverket har godkänt starten av en klinisk farmakokinetisk studie med läkemedelskandidaten CS014. Studien har utformats efter dialog med den amerikanska läkemedelsmyndigheten FDA och utgör ett regulatoriskt steg i förberedelserna inför den planerade Fas II-studien i pulmonell hypertension associerad med interstitiell lungsjukdom (PH-ILD). Här förklarar vi vad godkännandet innebär och hur...
Story
Så ska breddningen av utvecklingsfokus för CS014 förstås – en förklaring för investerare
Cereno Scientific har meddelat att bolaget breddar utvecklingsfokus för läkemedelskandidaten CS014 till pulmonell hypertension associerad med interstitiell lungsjukdom (PH-ILD). Beskedet innebär ett förtydligande av inriktningen för den fortsatta utvecklingen av CS014, med fokus på en patientgrupp med mycket stort medicinskt behov där både lungsjukdom och kärlsjukdom i lungorna samverkar. Beslutet är ett viktigt steg i...
Story
Så ska uppdateringen om Expanded Access Program (EAP) för CS1 förstås – en förklaring för investerare
Cereno Scientific har meddelat att den aktiva behandlingsperioden om 12 månader i bolagets Expanded Access Program (EAP) med läkemedelskandidaten CS1 nu har avslutats. Beskedet markerar en viktig operativ milstolpe i utvecklingen av CS1 och innebär att bolaget nu går vidare till nästa fas med databearbetning, analys och utvärdering. Vad är Expanded Access Program (EAP)? EAP...